Raphael Pharmaceutical (OTC: RAPH) posts Q1 loss and warns on going concern

Rhea-AI Filing Summary

Raphael Pharmaceutical Inc. reports first-quarter 2026 results showing a smaller loss but very limited liquidity and ongoing going-concern risk. The company generated no revenue and recorded a net loss of $229,000, down from $429,000 a year earlier, as research and development and general and administrative costs both fell roughly by half.

As of March 31, 2026, total assets were only $3,000, including $1,000 in cash, against current liabilities of $1,665,000, resulting in a stockholders’ deficit of $1,662,000 and an accumulated deficit of $10,397,000. Management explicitly states substantial doubt about the company’s ability to continue as a going concern and expects existing cash to fund operations only through the third quarter of 2026.

The cannabinoid-focused drug developer remains in the clinical and development stage, with no product revenue and plans to pursue additional U.S. and international clinical work in rheumatoid arthritis, autoimmune diseases, asthma and COVID-19-related indications. Management estimates it will need about $1 million for research and development and another $1 million for capital expenditures over the next 12 months, and plans to seek significant additional financing to support these activities.

Positive

• None.

Negative

• Severe liquidity constraints and going-concern warning: Cash was only $1,000 against $1,665,000 in current liabilities and a $1,662,000 stockholders’ deficit as of March 31, 2026, and management states substantial doubt about the company’s ability to continue as a going concern without significant new financing.

Insights

Biotech equity analyst

Raphael’s pipeline advances sit against acute funding pressure and a going‑concern warning.

Raphael Pharmaceutical is still a pre-revenue cannabinoid drug developer, with Q1 2026 net loss at $229,000 versus $429,000 a year earlier, driven by lower R&D and G&A spending. Operating cash outflow improved to $44,000, reflecting cost controls but also a very lean spend rate.

Balance sheet strength is a key concern. Total assets were just $3,000 with cash of $1,000 as of March 31, 2026, versus current liabilities of $1,665,000, leaving a stockholders’ deficit of $1,662,000. Management explicitly notes substantial doubt about the company’s ability to continue as a going concern absent new funding.

The company estimates needing about $1 million for R&D and $1 million for capital expenditures over the next 12 months while pursuing RA, autoimmune, asthma and COVID‑19 programs, including potential IND filings. Actual progress now depends heavily on securing additional capital; subsequent disclosures in future company filings will clarify whether financing is obtained and how the development plan evolves.

Key Figures

Net loss Q1 2026: $229,000 Net loss Q1 2025: $429,000 Cash and cash equivalents: $1,000 +5 more

8 metrics

Net loss Q1 2026 $229,000 Three months ended March 31, 2026

Net loss Q1 2025 $429,000 Three months ended March 31, 2025

Cash and cash equivalents $1,000 As of March 31, 2026

Current liabilities $1,665,000 As of March 31, 2026

Stockholders’ equity (deficit) ($1,662,000) As of March 31, 2026

Accumulated deficit $10,397,000 As of March 31, 2026

Net cash used in operations $44,000 Three months ended March 31, 2026

Planned 12‑month R&D spend $1,000,000 Management estimate for coming 12 months

Key Terms

going concern, Investigational New Drug, rheumatoid arthritis, Research Agreement, +2 more

6 terms

going concern financial

"This has led management to conclude that substantial doubt about the Company’s ability to continue as a going concern exists"

A going concern is a business that is expected to continue its operations and meet its obligations for the foreseeable future, rather than shutting down or selling off assets. This assumption matters to investors because it indicates stability and ongoing profitability, making the business a more reliable investment. Think of it as believing a restaurant will stay open and serve customers, rather than closing down suddenly.

Investigational New Drug regulatory

"we intend to submit an Investigational New Drug, or IND, application to the FDA and MOH"

An investigational new drug is a medication that is still being tested in clinical trials to determine if it is safe and effective for treating a specific condition. For investors, it represents a potential breakthrough that could lead to a new treatment and significant financial gains if successful, but also carries risks since it has not yet been approved for widespread use.

rheumatoid arthritis medical

"proof-of-concept clinical study ... for our lead product candidate for the treatment of RA in the United States"

A long-term autoimmune disease that causes the immune system to mistakenly attack the lining of joints, leading to pain, swelling, stiffness and progressive joint damage; it can also affect other organs. For investors, it matters because the condition drives sustained demand for treatments, influences clinical trial and regulatory outcomes, and affects healthcare spending and workplace disability—so drug approvals, new therapies or cost shifts can materially change the market value of companies involved.

Research Agreement financial

"we entered into a sponsored Research Agreement with Rambam, pursuant to which the Company agreed to fund a research project"

stockholders’ deficit financial

"Total stockholders’ equity (deficit) ... ( 1,662 )"

Stockholders’ deficit is the situation where a company’s total liabilities exceed its total assets, so the book value attributed to shareholders is negative. Think of it like a household with more outstanding debts than the value of its house and possessions—this can signal past losses or aggressive payouts and raises the risk that shareholders may be wiped out, diluted, or face difficulty when the company needs new financing. Investors watch it as a warning about solvency and long‑term financial health.

clinical trial medical

"we filed an application for a clinical trial with the Medical Cannabis Unit of the Ministry of Health of Israel"

A clinical trial is a carefully controlled study in which a new medicine, medical device, or treatment is tested on people to see if it is safe and effective. For investors it matters because trial results determine whether a product can win regulatory approval and reach patients, much like a road test decides if a new car can be sold; positive or negative results can sharply change a company’s prospects and stock value.

10-Q Quarterly Reports: What Changes Quarter to Quarter →

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

(Mark One)

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended: March 31, 2026

OR

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from            to           

Commission file number: 000-53002

Raphael Pharmaceutical Inc.

(Exact name of registrant as specified in its charter)

Nevada		26-0204284
(State or other jurisdiction of		(I.R.S. Employer
incorporation or organization)		Identification No.)

4 Lui Paster Street

Tel Aviv-Jaffa, Israel 6803605

(Address of principal executive offices)

(Zip Code)

(+972) 52-775-5072

(Registrant’s telephone number, including area code)

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
N/A		N/A		N/A

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer	☐	Accelerated filer	☐
Non-accelerated filer	☒	Smaller reporting company	☒
		Emerging growth company	☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

The number of shares of the registrant’s common stock, $0.01 par value, outstanding as of May 14, 2026: 20,176,418.

TABLE OF CONTENTS

			Page
	PART I
Item 1.	Financial Statements		1
Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations		2
Item 3.	Quantitative and Qualitative Disclosures About Market Risk		9
Item 4.	Controls and Procedures		10
	PART II
Item 1.	Legal Proceedings		11
Item 1A.	Risk Factors		11
Item 6.	Exhibits		11

i

Item 1. Financial Statements 

RAPHAEL PHARMACEUTICAL INC. AND ITS SUBSIDIARY

CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS

AS OF MARCH 31, 2026

UNAUDITED

U.S. DOLLARS IN THOUSANDS

INDEX

		Page
Condensed Consolidated Interim Balance Sheets		F-1
Condensed Consolidated Interim Statements of Comprehensive Loss		F-2
Condensed Consolidated Interim Statements of Changes in Stockholders’ Equity		F-3
Condensed Consolidated Interim Statements of Cash Flows		F-4
Notes to Condensed Consolidated Interim Financial Statements		F-5

- - - - - - - - - - - 

1

RAPHAEL PHARMACEUTICAL INC. AND SUBSIDIARY

CONDENSED CONSOLIDATED INTERIM BALANCE SHEETS

U.S dollars in thousands (except for share and per share data)

		As of March 31,				As of December 31,
		2026				2025
		(Unaudited)				(Audited)
Assets
Current assets:
Cash and cash equivalents		$	1			$	45
Other current assets			-				6
Total current assets			1				51
Fixed assets, net			2				2
Total assets		$	3			$	53
Liabilities and stockholders’ equity
Current liabilities:
Other accounts payables and accrued expenses			527				506
Short-term credit from related party			37				34
Payable to related party			1,101				946
Total current liabilities			1,665				1486
Stockholders’ equity (deficit):
Common stock, $0.01 par value:
Authorized: 50,000,000 shares at March 31, 2026 and December 31, 2025;
Issued and outstanding: 20,176,418 at March 31, 2026 and at December 31, 2025, respectively;			202				202
Additional paid-in capital			8,533				8,533
Accumulated deficit			(10,397	)			(10,168	)
Total stockholders’ equity (deficit)			(1,662	)			(1,433	)
Total liabilities and stockholders’ equity (deficit)		$	3			$	53

The accompanying notes are an integral part of the condensed consolidated interim financial statements.

F-1

RAPHAEL PHARMACEUTICAL INC. AND SUBSIDIARY

CONDENSED CONSOLIDATED INTERIM STATEMENTS OF COMPREHENSIVE LOSS

U.S dollars in thousands (except for share and per share data)

		Three months ended March 31,
		2026				2025
		Unaudited
Research and development expenses		$	37			$	72
General and administrative expenses			186				353
Operating loss			223				425
Total financial expense			6				4
Net loss		$	229			$	429
Basic and diluted net loss per share		$	0.01			$	0.02
Weighted average number of shares of common stock used in computing basic and diluted net loss per share			20,176,418				19,626,418

The accompanying notes are an integral part of the condensed consolidated interim financial statements.

F-2

RAPHAEL PHARMACEUTICAL INC. AND SUBSIDIARY

CONDENSED CONSOLIDATED INTERIM STATEMENTS OF CHANGES IN STOCKHOLDERS’ EQUITY (UNAUDITED)

U.S dollars in thousands (except for share and per share data)

		Common stock								Additional paid-in				Accumulated				Total
		Number				Amount				capital				deficit				equity
Balance as of January 1, 2025			18,701,418			$	187			$	7,960			$	(8,889	)		$	(742	)
Issuance of common stock and warrants			575,000				6				234				-				240
Share-based compensation			350,000			$	3				194							$	197
Net loss			-				-				-				(429	)			(429	)
Balance as of March 31, 2025			19,626,418			$	196			$	8,388			$	(9,318	)		$	(734	)

		Common stock								Additional paid-in				Accumulated				Total
		Number				Amount				capital				deficit				equity
Balance as of January 1, 2026			20,176,418			$	202			$	8,533			$	(10,168	)		$	(1,433	)
Issuance of common stock and warrants			-				-				-				-				-
Share based compensation			-			$	-				-				-			$	-
Net loss			-				-				-				(229	)			(229	)
Balance as of March 31, 2026			20,176,418			$	202			$	8,533			$	(10,397	)		$	(1,662	)

The accompanying notes are an integral part of the condensed consolidated interim financial statements.

F-3

RAPHAEL PHARMACEUTICAL INC. AND SUBSIDIARY

CONDENSED CONSOLIDATED INTERIM STATEMENTS OF CASH FLOWS

U.S dollars in thousands (except for share and per share data)

		Three months ended March 31,
		2026				2025
Cash flows from operating activities
Net loss		$	(229	)		$	(429	)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation			(*	)			(*	)
Share-based compensation			-				197
Interest accrued			3				-
Changes in:
Other current assets			6				(35	)
Account payables and related parties			176				58
Net cash used in operating activities			(44	)			(209	)
Cash flows from investing activities
Purchase of fixed assets			-				-
Net cash used in investing activities			-				-
Cash flows from financing activities
Issuance of common stock and warrants**			-				240
Net cash provided by financing activities			-				240
Change in cash and cash equivalents			(44	)			31
Cash and cash equivalents at the beginning of the period			45				19
Cash and cash equivalents at the end of the period		$	1			$	50

(*) less than $1 thousand

The accompanying notes are an integral part of the condensed consolidated interim financial statements.

F-4

RAPHAEL PHARMACEUTICAL INC. AND SUBSIDIARY

NOTES TO CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS (UNAUDITED)

U.S dollars in thousands (except for share and per share data)

NOTE 1:- GENERAL

a. Raphael Pharmaceutical Inc (formerly Easy Energy, Inc.) (the “Company”) was incorporated under the laws of the State of Nevada on May 17, 2007. The Company is headquartered in Tel Aviv-Jaffa, Israel.

On October 8, 2020, the Company and its stockholders entered into a Share Exchange Agreement (the “Share Exchange”) with an Israeli pharmaceutical company (“Raphael”), according to which, among other matters, all shareholders of Raphael will sell and convey the entire holdings in Raphael to the Company such that following the Share Exchange, the shareholders of Raphael will hold 90% of the issued and outstanding common stock of the Company, and the existing shareholders of the Company will hold the remaining 10% of the issued and outstanding common stock.

On May 14, 2021, the Company’s board of directors (the “Board”) and stockholders approved a 1-for-100 reverse split of the Company’s common stock, which was implemented and became effective as of May 14, 2021. The reverse split combined each one hundred (100) shares of the Company’s issued and outstanding common stock into one share of common stock. No fractional shares were issued in connection with the reverse split, and any fractional shares resulting from the reverse split were rounded up to the nearest whole share. 

On May 14, 2021, Raphael and the Company, completed the Share Exchange pursuant to which 9,459,253 common stock were issued to the shareholders of Raphael so that they became the holders of 90% of the issued and outstanding common stock of the Company immediately after the Share Exchange while the Company’s shareholders held, following the Share Exchange, 1,051,028 common stock which represents 10% of the Company. On May 19, 2021, as agreed by the parties to the Share Exchange, the Company changed its name to Raphael Pharmaceutical Inc. Following such Share Exchange, Raphael’s activities are the sole activities of the Company. 

The Share Exchange was accounted for as a reverse recapitalization which is outside the scope ASC 805, “Business Combinations” (“ASC 805”), as the Company, the legal acquirer, is considered a non-operating public shell, and is therefore not a business as defined in ASC 805. As the shareholders of Raphael received the largest ownership interest in the Company, Raphael was determined to be the “accounting acquirer” in the Share Exchange. As a result, the historical financial statements of the Company were replaced with the financial statement of Raphael for all periods presented.

Company’s common stock began public trading on the over-the-counter market in the U.S. in January 2023 under the symbol “RAPH”.

b. Going concern and management plans

The accompanying financial statements have been prepared on a going-concern basis, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. Since its inception, the Company has devoted substantially all of its efforts to research and development, clinical trials, and raising capital. The Company is still in its development and clinical stage and has not yet generated revenues. The extent of the Company's future operating losses and the timing of becoming profitable are uncertain. As of March 31, 2026, the Company's accumulated deficit was $10,397. The Company has funded its operations to date primarily through equity financing and the issuance of a loan.  

Additional funding will be required to complete the Company’s research and development and clinical trials, to attain regulatory approvals, to begin the commercialization efforts of the Company’s product and to achieve a level of sales adequate to support the Company’s cost structure.

F-5

RAPHAEL PHARMACEUTICAL INC. AND SUBSIDIARY

NOTES TO CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS (UNAUDITED)

U.S dollars in thousands (except for share and per share data)

NOTE 1:- GENERAL (Cont.)

Management’s plans include, but are not limited to, raising capital in the United States. There can be no assurance that it will be able to successfully raise additional financing, including in a public offering, or obtain additional financing on a timely basis or on terms acceptable to the Company, or at all.

Management expects that the Company will continue to generate losses from the development, clinical development and regulatory activities of its product, which will result in negative cash flow from operating activity. This has led management to conclude that substantial doubt about the Company’s ability to continue as a going concern exists in the event that additional funding does not occur. If such sufficient financing is not received timely, the Company will not have sufficient cash flows and liquidity to finance its business operations as currently contemplated and would then need to pursue a plan to license its assets, seek to be acquired by another entity, cease operations and/or seek bankruptcy protection. The Company’s financial statements do not reflect any adjustments that might result from the outcome of this uncertainty.

NOTE 2:- SIGNIFICANT ACCOUNTING POLICIES

These unaudited interim financial statements should be read in conjunction with the audited financial statements and accompanying notes for the year ended December 31, 2025. The significant accounting policies applied in the annual financial statements of the Company as of December 31, 2025, are applied consistently in these interim financial statements.

NOTE 3:- UNAUDITED INTERIM FINANCIAL STATEMENTS

The accompanying unaudited condensed consolidated interim financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 10 of U.S. Securities and Exchange Commission Regulation S-X. Accordingly, they do not include all the information and footnotes required by generally accepted accounting principles for complete financial statements. In the opinion of management, all adjustments considered necessary for a fair presentation have been included (consisting only of normal recurring adjustments except as otherwise discussed). For further information, reference is made to the consolidated financial statements and footnotes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025. Operating results for the three months ended March 31, 2026 are not necessarily indicative of the results that may be expected for the year ending December 31, 2026.

F-6

RAPHAEL PHARMACEUTICAL INC. AND SUBSIDIARY

NOTES TO CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS (UNAUDITED)

U.S dollars in thousands (except for share and per share data)

NOTE 4:- SHAREHOLDERS’ EQUITY

During the first quarter of 2026, there were no new issuances of common stock, warrants or share-based compensation.

NOTE 5:- RELATED PARTY BALANCES AND TRANSACTIONS

A. Balances

The following related party payables are included in accounts payable and accrued expenses.

		As of March 31,				As of December 31,
		2026				2025
		(Unaudited)				(Audited)
Payables to related parties - Officers (*)			1,101				946
Short-term credit from a related party (**)			37				34

(*) Relates to Chief Executive Officer’s (“CEO”),Chief Financial Officer’s (“CFO”), and Chief Technology Officer’s services and payments on behalf of the Company.

(**) Relates to a director. The director was appointed during the first quarter of 2025. The Company’s CEO and CFO are guarantees for the repayment of the loan.

B. Transactions

		Three months ended March 31,
		2026				2025
Consulting services			96				132
Stock-based compensation			-				197
CFO fee			36				36
			132				365

NOTE 6:- SUBSEQUENT EVENTS

In accordance with ASC 855-10, the Company’s management reviewed all material events through the date of this consolidated financial statements and determined that there are no additional material subsequent events to report.

F-7

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

The following discussion and analysis of our financial condition and results of operations should be read in conjunction with the accompanying condensed consolidated financial statements and related notes included elsewhere in this Quarterly Report on Form 10-Q, or the Quarterly Report.

On May 14, 2021, Raphael Pharmaceutical Ltd., an Israeli company, and Easy Energy, Inc., a Nevada corporation, completed a share exchange agreement, or the Share Exchange, pursuant to which the shareholders of Raphael Pharmaceutical Ltd. became the holders of 90% of the issued and outstanding share capital of Easy Energy, Inc., while Easy Energy, Inc.’s shareholders hold, following the share exchange, 10% of Easy Energy, Inc. On May 19, 2021, as agreed by the parties to the Share Exchange, Easy Energy, Inc. changed its name to Raphael Pharmaceutical Inc. Unless otherwise mentioned or unless the context requires otherwise, when used in this Quarterly Report, the terms “Raphael,” “Company,” “we,” “us,” and “our” refer to Raphael Pharmaceutical Inc. and its subsidiary, Raphael Pharmaceutical Ltd., or Raphael Israel. References to Easy Energy are to Easy Energy, Inc. Unless otherwise mentioned or unless the context requires otherwise, the information provided in this Quarterly Report relates to Raphael Israel.

Forward-Looking Statements

This Quarterly Report contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws, which includes information relating to future events, future financial performance, strategies, expectations, competitive environment and regulation. Words such as “may,” “will,” “should,” “could,” “would,” “predicts,” “potential,” “continue,” “expects,” “anticipates,” “future,” “intends,” “plans,” “believes,” “estimates,” and similar expressions, as well as statements in future tense, identify forward-looking statements. Forward-looking statements should not be read as a guarantee of future performance or results and may not be accurate indications of when such performance or results will be achieved. Forward-looking statements are based on information we have when those statements are made or our management’s good faith belief as of that time with respect to future events and are subject to significant risks and uncertainties that could cause actual performance or results to differ materially from those expressed in or suggested by the forward-looking statements. Important factors that could cause such differences include, but are not limited to:

● the regulatory pathways that we may elect to utilize in seeking U.S. Food and Drug Administration, or FDA, European Medicines Agency, or EMA, and other regulatory approvals, if any;

● obtaining (and the cost thereof) FDA and EMA approval of, or other regulatory action in Europe or the United States and elsewhere with respect to our product candidates;

● the commercial launch and future sales of our product candidates and our advancement of product candidates for other indications in our pipeline;

● the potential cost of our rheumatoid arthritis product candidate, or RA, and RA product candidate, respectively, for patients;

● our expectations regarding the timing of commencing clinical trials;

● our expectations regarding the supply of the active pharmaceutical ingredient for our product candidates;

● third-party payor reimbursement for our product candidates;

● our estimates regarding anticipated expenses, capital requirements and our needs for additional financing;

● completion and receival of favorable results of clinical trials for our product candidates; and

● the filing by us, and the subsequent issuance of patents to us, by the U.S. Patent and Trademark Office, or USPTO, and other governmental patent agencies.

2

The foregoing does not represent an exhaustive list of matters that may be covered by the forward-looking statements contained herein or risk factors that we are faced with that may cause our actual results to differ from those anticipated in our forward-looking statements. Please see “Item 1A. Risk Factors” in Part I of our Annual Report on Form 10-K for the fiscal year ended December 31, 2025 for additional risks that could adversely impact our business and financial performance.

Moreover, new risks regularly emerge and it is not possible for our management to predict or articulate all the risks we face, nor can we assess the impact of all risks on our business or the extent to which any risk, or combination of risks, may cause actual results to differ from those contained in any forward-looking statements. All forward-looking statements included in this Quarterly Report are based on information available to us on the date of this Quarterly Report. Except to the extent required by applicable laws or rules, we undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise. All subsequent written and oral forward-looking statements attributable to us or persons acting on our behalf are expressly qualified in their entirety by the cautionary statements contained above and throughout this Quarterly Report.

In this Quarterly Report, unless otherwise specified, all dollar amounts are expressed in United States dollars. Except as otherwise indicated by the context, references in this Quarterly Report to “Raphael,” “Company”, “we,” “us” and “our” are references to Raphael Pharmaceutical Inc., a Nevada corporation, together with its consolidated subsidiaries.

Overview

We are a pharmaceutical drug research and development company focused on the discovery and clinical development of life-improving drug therapies based on cannabinoids, including cannabidiol, or CBD, oil. Unless indicated otherwise, we plan on using oil derived from CBD strains with low levels of Tetrahydrocannabinol, or THC. All references to the use of CBD in our product candidates refer to CBD strains with less than 0.3% of THC.

In December 2024 we completed a proof-of-concept clinical study, or Study, for our lead product candidate for the treatment of RA in the United States. Encouraged by the promising results of the Study, we will continue to investigate our product for the treatment of autoimmune diseases.

In addition, we are aiming to develop a novel treatment for asthma. At Rambam Health Care Campus, Rambam Med-Tech Ltd., or Rambam, we have successfully conducted studies using human-derived immune cells and mouse models to advance our understanding both COVID-19 and RA products. Due to the similarity of COVID-19 and asthma symptoms, such studies also advance our understanding of asthma and its treatment. Since the volume of COVID-19 testing has been decreasing, we decided to leverage our knowledge and understanding of COVID-19 to study asthma as well.

On February 9, 2022, we filed an application for a clinical trial with the Medical Cannabis Unit of the Ministry of Health of Israel, or MOH. On February 16, 2022 we submitted an application with the Helsinki Committee at Rambam for a clinical trial in COVID-19 patients.

In November 2022, we submitted a proposal to the Ministry of Health of Israel, or MOH for a clinical trial of a cannabis-based drug intended to alleviate the deterioration of COVID-19 patients.

On March 27, 2023, the MOH accepted our proposal for a clinical trial of a cannabis-based drug intended to alleviate the deterioration of COVID-19 patients.

3

In April 2024 we began the Study in the U.S., leveraging insights from the pre-clinical experiments we have conducted at the Rambam. This Study aimed to evaluate the Company’s Cannabinoid based formula, or Raphael’s Formula, in patients with active RA. The single-group Study was managed by MindMate, Inc. dba Citruslabs, or Citruslabs, and conducted in Santa Monica, California, U.S., under Institutional Review Board, or IRB, approval, in compliance with applicable FDA regulations and in accordance with applicable industry standards and regulations. An IRB is an appropriately constituted group that has been formally designated to review and monitor biomedical research involving human subjects.

On December 23, 2024, upon a successful completion of the Study, we received the Study results with overall findings that emphasize the clinical potential of Raphael’s Formula and suggest that it may have beneficial effects on symptom management and overall well-being for individuals with RA. For more information about the Study results, see “Item 1. Business - Research and Clinical Development Strategy”.

In August 2025, we announced the completion of product development and the launch of our proprietary natural formula under the “RaphaWell” brand for RA support in the U.S. This follows the successful completion of a clinical trial conducted under IRB approval and is in full compliance with FDA regulations, including participants with severe RA. The finalized “RaphaWell” product is intended be sold as a standalone clinically tested dietary supplement targeting the growing wellness market. The “RaphaWell” formula is 100% natural, plant-based, and was associated with no reported side effects during the Study, addressing a significant unmet need in RA symptom management. Raphael’s “RaphaWell” formula has undergone clinical testing, which to our belief, proved its credibility and efficacy.

In November 2025, we, jointly with the Medical Cannabis Research and Innovation Center and Rambam, filed a provisional patent application with the USPTO titled “Raphael Pharmaceutical, Inc. / Rambam MedTech Formula for Treating Neutrophil-Dominant Autoimmune Diseases (including RA)” (Application No. 63/911,729). The application covers the use of our highly purified cannabinoid-based technology platform in the treatment of neutrophil-dominant autoimmune diseases, including our lead product candidate for RA, as well as psoriatic arthritis, inflammatory bowel disease, systemic lupus erythematosus with neutrophil involvement, and gout.

As we move forward, our focus will be on further investigating mechanisms and refining Raphael’s Formula through continued pre-clinical research. Our goal is to ensure that the formula meets all the necessary standards and regulations set forth by the FDA, allowing us to progress towards clinical treatments.

Our vision is to emerge as a pioneering company at the forefront of formulating pharmaceutical drugs that harness the potential of purified cannabinoids and full-spectrum CBD oil. Our primary mission is to cater to the unmet medical requirements of patients grappling with various disorders, with a particular focus on conditions linked to inflammation, such as autoimmune diseases, asthma, RA and COVID-19.

By leveraging our expertise in this field, we are committed to providing innovative solutions to improve the lives of those afflicted with these challenging medical conditions. Through our dedication to research, development, and compassionate care, we aim to contribute significantly to the well-being of patients worldwide, offering them much-needed relief and hope for a better future.

In order to achieve our goal, we have and will continue to build an experienced team of senior executives and scientists, with experience in all facets of pharmaceutical research and development, drug formulation, clinical trial execution and regulatory submissions. We intend to leverage the knowledge of our team in order to complete the clinical trials needed to receive approvals of our product candidates from applicable regulatory authorities.

Initially, we intend to obtain approvals for our product candidates from the FDA, and the Medical Cannabis Unit of the MOH. Upon obtaining FDA approvals, or in the event that we are not successful in obtaining such approvals, we intend to apply for European Medicines Agency, or EMA, and other countries’ governmental regulatory agencies approvals for our product candidates. If we are successful in obtaining FDA approvals for our product candidates, we intend to enter into royalty agreements with good manufacturing practice, or GMP, approved medical manufactures and distributors, having them use our medical formulas for the purpose of growing, cultivating, manufacturing, and distributing Raphael Pharmaceutical medical indications in their designated territories.

4

For this purpose, in October 2022, we entered into an agreement with the Medical Cannabis Research and Innovation Center at Rambam for the development of a new, patentable formulation that combines purified cannabinoids to treat rheumatoid diseases.

The overall objective of this study is to identify a novel cannabinoid based patentable formulation to treat Rheumatoid diseases. Specifically, to investigate combination of purified cannabinoids to downregulate inflammation related to Rheumatoid diseases. We propose to base our study on data derived from Dr. Igal Louria-Hayon’s studies (Helsinki # 0442-20-RMB) on the evaluation of the immune regulation properties of cannabinoids on the immune system and the data derived from the cannabinoids receptors study (Helsinki # 0331-20-RMB). We will analyze the activation of cannabinoid receptors on mouse models and will study the role of purified cannabinoid as a potential to develop a novel patentable formulation to treat RA.

Our discovery platform currently focuses the use of CBD oil, one of the cannabinoids in cannabis plants, as the active pharmaceutical ingredient, or API, for our RA product candidate and COVID-19 product candidate. Research results published in 2018 (“Translational Investigation of the Therapeutic Potential of Cannabidiol (CBD): Toward a New Age”) has shown that there may be benefits to treading medical conditions, or their effects, with cannabinoids, and more specifically, with CBD, which may help reduce chronic pain by impacting endocannabinoid receptor activity, reducing inflammation and interacting with neurotransmitters. This research has also shown that CBD may have neuroprotective properties, and could have the ability to (i) reduce anxiety and depression, (ii) alleviate cancer-related symptoms, (iii) reduce acne and (iv) benefit heart health.

Over the last few years, pharmaceutical drug products that include parts of the cannabis plant have begun to receive regulatory approvals for use in patients suffering from certain disorders, as highlighted below.

● Nabiximols, better known under the tradename Sativex, is a botanical mouth spray consisting of natural THC and CBD extracts, that received approval in the United Kingdom in 2010 for the alleviation of multiple sclerosis, or MS, symptoms like spasticity, pain and overactive bladder.

● Dronabinol, better known under the name Marinol, contains mainly THC and is a partial agonist of the cannabinoid receptor type 1, or CB1, in the nervous system and a partial agonist of the cannabinoid receptor type 2, or CB2, in the periphery that activates appetite, mood, cognition, memory and perception. Dronabinol received FDA-approval for use in the U.S. in 1985 for treatment of anorexia in acquired immunodeficiency syndrome, or AIDS, patients and for the prevention of chemotherapy-induced nausea and vomiting, or CINV. A Lack of randomized controlled trials, or RCTs, makes a recommendation for usage of dronabinol as a third-line treatment for CINV difficult. Dronabinol in the form of an oral tablet is known under the trade name Namisol. It has high bioavailability and a long shelf life and is indicated for MS, chronic pain and behavioral disturbances in dementia patients.

● Nabilone, better known under the tradename Cesamet, contains primarily THC, is approved for use as an anti-emetic and adjunctive analgesic for neuropathic pain, CINV and treatment for anorexia in AIDS patients in Canada, Mexico, the UK and the U.S. Its main usage today is as adjunct medicine for chronic pain management.

In light of the past regulatory approvals for other pharmaceutical drug products and, more specifically, the potential beneficial effects of CBD and other parts of the cannabis plant, we believe that a drug discovery platform based on CBD may offer new and differentiated treatment options for patients. Prior regulatory approvals of other companies’ pharmaceutical drug products do not serve as an indication as to the ability or likelihood that we receive regulatory approval to commercialize any of our product candidates.

After four successful years of pre-clinical research at the laboratories of Rambam, which paved the way for the Study in RA patients, we are now advancing our efforts to further develop our product candidates.

5

Following the completion of the Study, we intend to submit an Investigational New Drug, or IND, application to the FDA and MOH. See “Item 1. Business - Research and Clinical Development Strategy - Clinical Development Plan” for additional information on the ongoing pre-clinical trial and our planned clinical trial for our RA product candidate.

In addition, with respect to our COVID-19 product candidate, our clinical research partners have been focused on the effect of cannabinoids and cannabis extracts on immune cells which induce acute inflammation. This study will begin in the pre-clinical level in immune cell models and, subject to positive results that exhibit downregulation of pro-inflammatory cytokines by cannabis extract, the study was completed successfully. Following the completion of the pre-clinical study, a mice model was conducted to analyze for acute inflammation, which resembles the immunopathology of COVID-19. The mice model was successfully completed and we have registered for a clinical trial in patients with the MOH.As a pharmaceutical research and clinical development company we do not own or operate, and currently do not intend on creating an in-house team to manufacture and commercialize our pharmaceutical drug products, if any, that receive regulatory approval allowing for commercialization. We currently rely, and expect to continue to rely, on third parties for the manufacturing of our product candidates for preclinical and clinical testing, as well as for commercial manufacturing of any pharmaceutical drug products for which we may receive regulatory approval. Subject to the receipt of such regulatory approvals, we intend on cooperating with manufacturers and other third parties to manufacture and commercialize approved pharmaceutical drug products.

Critical Accounting Estimates

Our financial statements are prepared in accordance with U.S. GAAP. There are no critical accounting estimates for the years ended December 31, 2025, and 2024. Also, please see Note 2 of Part I, Item 1 of this Quarterly Report for the summary of significant accounting policies.

Results of Operations

Three months ended March 31, 2026, compared to the three months ended March 31, 2025

Revenues. We had no revenue during the three months ended March 31, 2026, and March 31, 2025.

Research and Development Expenses. Our research and development expenses totaled $37,000 for the three months ended March 31, 2026, representing a decrease of $35,000, or 49%, compared to $72,000 for the three months ended March 31, 2025. The decrease was primarily attributable to a decrease in our chief Technology Officer's compensation.

General and Administrative Expenses. Our general and administrative expenses totaled $186,000 for the three months ended March 31, 2026, representing a decrease of $167,000, or 47%, compared to $353,000 for the three months ended March 31, 2025. The decrease was primarily due to a decrease in share based compensation paid to a director.

Operating Loss. Our operating loss totaled $223,000 for the three months ended March 31, 2026, representing a decrease of $202,000, or 48%, compared to $425,000 for the three months ended March 31, 2025. The decrease was primarily due to a decrease in our research and development expenses, and a decrease in our general and administrative costs.

Financial expense, net. We recognized financial expense, net, of $6,000 for the three months ended March 31, 2026, representing an increase of $2,000, or 50%, compared to financial expense, net of $4,000 for the three months ended March 31, 2025. The Company considers the increase to be immaterial.

Net Loss. As a result of the foregoing, our net loss totaled $229,000 for the three months ended March 31, 2026, representing a decrease of $200,000, or 47%, compared to $429,000 for the three months ended March 31, 2025. The decrease was primarily due to a decrease in our research and development expenses and a decrease in our general and administrative costs.

6

Liquidity and Capital Resources

Since inception, we have funded our operations primarily through our founder’s capital and capital received from Easy Energy, Inc. As of March 31, 2026, we had $1,000 in cash and cash equivalents, and have invested most of our available cash funds in ongoing cash accounts.

Net cash used in operating activities was $44,000 for the three-months period ended March 31, 2026, compared with net cash used in operating activities of $209,000 for the corresponding period in 2025. The decrease in the net cash used in operating activities during the three-months period ended March 31, 2026, compared to the same period in 2025, was primarily due to a decrease in our net loss, offset by eliminating share based compensation and an increase in account payables.

There was no net cash used in investing activities for the three months period ended March 31, 2026 and for the same period in 2025.

There was no net cash used in financing activities for the three months period ended March 31, 2026 compared to $240,000 for the same period in 2025. The decrease in net cash provided by financing activities during the three months period ended March 31, 2026 compared to the corresponding period in 2025 was due to a decrease in issuance of common stock and warrants.

On December 24, 2024, we received a short-term loan from certain lender in a total of NIS 150 thousand ($41 thousand, based on the NIS-USD exchange rate on December 24, 2024, the date the agreement was signed). The loan was originally repayable within four months and included a risk premium of NIS 12 thousand, exclusive of value-added tax (VAT). Since we did not repay the loan within the original timeframe, the total interest and penalties incurred amounted to NIS 54 thousand.

During the year ended December 31, 2025, we repaid an aggregate amount of NIS 96.9 thousand. As of December 31, 2025, the remaining balance of the loan, including accrued interest, is NIS 107.1 thousand ($34 thousand, based on the NIS-USD exchange rate on December 31, 2025), and is included within short-term credit from a related party in the consolidated balance sheets.

Our Chief Executive Officer and Chief Financial Officer are guarantors for the repayment of the loan.

Our Chief Executive Officer occasionally makes repayments of the loan on behalf of the company.

During the Period ended March 31, 2025, we accrued an aggregate amount of NIS 9.6 thousand. As of March 31, 2026, the remaining balance is NIS 116.7 thousand ($37 thousand, based on the NIS-USD exchange rate on March 31, 2026).

Off Balance Sheet Arrangements

Rambam Research Agreement

On July 17, 2019, we entered into a sponsored Research Agreement with Rambam, pursuant to which the Company agreed to fund a research project, to be performed by Rambam, with a research plan aimed at identifying the effects of different cannabis strains on the function of immune cells. On October 28, 2020, the Company and Rambam agreed to expand the research plan to study the anti-inflammatory activities of cannabis extracts in an RA mouse model. On February 15, 2021, the Company and Rambam agreed to further expand the research plan to study the effect of cannabis extracts on the immunopathology of the COVID-19 disease. The sponsored Researched Agreement is for an initial term of 48 months. On October 23, 2022, the Company and Rambam entered into a supplement to the Research Agreement, or the Supplement Agreement, pursuant to which the Company exercised an option to extend the Research Agreement by additional two years until December 31, 2024.Pursuant to the Research Agreement, we agreed to pay Rambam $1.4 million in four equal payments, due on the first day of August on each successive year from 2019 through 2022. Pursuant to the Supplement Agreement, we agreed to pay Rambam $960,000 plus VAT in four biannual payments from May 2023 through December 2024. Such amount was later amended to $470,000 plus VAT out of which we paid $120,000. Furthermore, in accordance with the terms of the Research Agreement, we and Rambam will have joint ownership of any IP created as a result of research programs covered by such agreement. In connection with the Research Agreement, Rambam agreed not to work, study or develop any technologies with other entities that compete with our work with Rambam for our COVID-19 product candidate or RA product candidate for a term of three and seven years, respectively, from the end of the parties’ collaboration with respect to the COVID-19 product candidate and seven years from the end of the term of the Research Agreement with respect to the RA product candidate. Subject to commercial sales of any product candidate using the IP created as a part of the research covered by such agreement, Raphael Israel is required to pay Rambam a royalty in an amount equal to 6% of all net sales, subject to certain deductions, such as taxes paid by any purchaser, transportation and shipping costs, and other customary deductions.

7

On December 25, 2023, the Company received an extension to pay the remaining $350,000 pursuant to the Research Agreement until the end of June 2024, however, since the remaining amount was not paid on time, an additional amount of $57,000 was added to the remaining balance. On July 28, 2025, the Company received an extension to pay the remaining balance until the end of April 2026. As of the date of this Quarterly Report, the Company has made all four of the four equal payments due pursuant to the Research Agreement, for a total amount of $1.4 million and $295,000 for the Supplement Agreement (out of the remaining $577,000). As of the date of this Quarterly Report, the outstanding balance is approximately $300,000 and VAT (based on the NIS-USD exchange rate on March 31, 2026).

Service Agreement with our Chief Technology Officer

Our Chief Technology Officer, Dr. Igal Louria Hayon, provides services to our Company pursuant to a service agreement, by and between the Company and Dr. Igal Louria Hayon. Pursuant to the terms thereof Dr. Hayon provides consulting services the Company to engage with an array of science consultants and to coordinate collaborations with hospitals on medical cannabis research. Pursuant to such agreement, we agreed to pay our Chief Technology Officer 15% of the Company’s net royalty’s income from worldwide sales of any of the Company’s cannabis-based medical indications treating COVID-19. Pursuant to Dr. Hayon’s service agreement, in the event we will apply for any clinical trial of cannabis-based treatment or will begin any other new cannabis related research, the Corporation will grant Dr. Hayon warrants to purchase up to 350,000 shares of Common Stock at an exercise price of $0.01. On May 1, 2024, the milestone was met and the Company granted to Dr. Igal Louria Hayon warrants to purchase up to 350,000 shares of Common Stock of the Company at an exercise price of $0.01. The warrants were exercised in November 2025.

On March 3, 2025, we entered into a new service agreement with our Chief Technology Officer, substantially on the same terms as the agreement described above, effective as of January 1, 2025 Pursuant to such service agreement, we agreed to pay our Chief Technology Officer a monthly fee of $24,000 and to reimburse him with certain expenses related to his scientific work.

On December 27, 2025 we extended such service agreement with our Chief Technology Officer, effective as of January 1, 2026 and until December 31, 2027. Pursuant to the extension to such service agreement, we agreed to pay our Chief Technology Officer a monthly fee of $12,000 and to reimburse him with certain expenses related to his scientific work.

The Company may terminate the service agreement prior to the expiration of its term upon 120 days advance notice and the payment to Dr. Hayon of a termination fee equal to the monthly fees payable through the expiration of its term.

Except for the above, we have not engaged in any off-balance sheet arrangements, such as the use of unconsolidated subsidiaries, structured finance, special purpose entities or variable interest entities.

We do not believe that our off-balance sheet arrangements and commitments have or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that is material to investors.

Current Outlook

We have financed our operations to date primarily through proceeds from our founder’s capital and issuance of shares and warrants. We have incurred losses and generated negative cash flows from operations since inception. To date we have not generated revenue, and we do not expect to generate significant revenues from the sale of our products in the near future.

8

We do not believe that our current cash on hand will be sufficient to fund our projected operating requirements. This raises substantial doubt about our ability to continue as a going concern. At this time, there is no guarantee that we will be able to obtain an adequate level of financial resources required for the short and long-term support of our operations or that we will be able to obtain additional financing as needed, or meet the conditions of such financing, or that the costs of such financing may not be prohibitive. These conditions raise substantial doubt about our ability to continue as a going concern for a period within one year from the date of the financial statements included elsewhere in this Quarterly Report.

As of March 31, 2026, our cash and cash equivalents were $1,000. We believe that our existing cash and cash equivalents will be sufficient to fund our projected cash requirements through the third quarter of 2026. Therefore, we will require significant additional financing in the near future to fund our operations. We currently anticipate that we will require approximately $1 million for research and development activities over the course of the next 12 months. We also anticipate that we will require approximately $1 million for capital expenditures over such 12-month period, which consists primarily of expenditures for clinical trials and general Company operating costs.

In addition, our operating plans may change as a result of many factors that may currently be unknown to us, and we may need to seek additional funds sooner than planned. Our future capital requirements will depend on many factors, including:

● our research and development efforts, including our ability to finish research and development projects or product development within the allotted or expected timeline;

● the cost, timing and outcomes of seeking to commercialize our products in a timely manner;

● our ability to generate cash flows;

● economic weakness, including inflation, or political instability in particular foreign economies and markets;

● government regulation in our industry, and more specifically, the costs and timing of obtaining regulatory approval or permits to launch our technology in various geographical markets; and

● the costs of, and timing for, strengthening our manufacturing agreements for production of our wave energy systems.

Until we can generate significant revenues, if ever, we expect to satisfy our future cash needs through our existing cash, cash equivalents and short-term deposits, loans, or debt or equity financings. We cannot be certain that additional funding will be available to us on acceptable terms, if at all. If funds are not available, we may be required to delay, reduce the scope of, or eliminate research or development plans for, or commercialization efforts with respect to, one or more applications of our products. This may raise substantial doubts about our ability to continue as a going concern.

Item 3. Quantitative and Qualitative Disclosures About Market Risk.

Not applicable.

9

Item 4. Controls and Procedures

Management’s Conclusions Regarding Effectiveness of Disclosure Controls and Procedures

As of March 31, 2026, we conducted an evaluation, under the supervision and participation of management including our Chief Executive Officer and Chief Financial Officer, of the effectiveness of our disclosure controls and procedures (as defined in Rule 13a-15(e) and Rule 15d-15(e) of the Securities Exchange Act of 1934, as amended). There are inherent limitations to the effectiveness of any system of disclosure controls and procedures. Accordingly, even effective disclosure controls and procedures can only provide reasonable assurance of achieving their control objectives.

Based upon this evaluation, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures are effective at the reasonable assurance level as of March 31, 2026.

Internal Control over Financial Reporting

There were no changes in our internal control over financial reporting during the fiscal quarter ended March 31, 2026, that materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

Management is responsible for establishing and maintaining adequate internal control over financial reporting, as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act. Our internal control over financial reporting is designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with accounting principles generally accepted in the United States of America.

Because of inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Therefore, even internal controls determined to be effective can provide only reasonable assurance with respect to financial statement preparation and presentation. The effectiveness of our internal control over financial reporting is subject to various inherent limitations, including cost limitations, judgments used in decision making, assumptions about the likelihood of future events, the possibility of human error, and the risk of fraud. The projection of any evaluation of effectiveness to future periods is subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with policies may deteriorate. Because of these limitations, there can be no assurance that any system of internal control over financial reporting will be successful in preventing all errors or fraud or in making all material information known in a timely manner to the appropriate levels of management.

This Quarterly Report does not include an attestation report of the company’s registered public accounting firm regarding internal control over financial reporting. Management’s report was not subject to attestation by the company’s registered public accounting firm pursuant to rules of the Commission that exempt from this requirement issuers that are neither accelerated filers nor large accelerated filers.

10

PART II - OTHER INFORMATION

Item 1. Legal Proceedings

There have been no material changes to our legal proceedings as described in “Item 3. Legal Proceedings” in our Annual Report on Form 10-K, as filed with the SEC on March 31, 2026.

Item 1A. Risk Factors

There have been no material changes to our risk factors from those disclosed in “Item 1A. Risk Factors” in our Annual Report on Form 10-K, as filed with the SEC on March 31, 2026.

Item 6. Exhibits

EXHIBIT INDEX

Exhibit No.		Description
3.1		Restated Certificate of Incorporation (incorporated by reference from Amendment No. 2 to our registration statement on Form 10, filed on September 23, 2021).
3.2		Bylaws (incorporated by reference from Amendment No. 2 to our registration statement on Form 10, filed on September 23, 2021).
10.1		English Translation of the Amendment to the Service Agreement by and between the Company and Dr. Igal Louria Hayon, dated December 27, 2025 (incorporated by reference to Exhibit 10.10 in our annual report on Form 10-K filed on March 31, 2026).
10.2		English Translation of the Amendment to the Service Agreement by and between the Company and Guy Ofir, dated December 27, 2025 (incorporated by reference to Exhibit 10.11 in our annual report on Form 10-K filed on March 31, 2026).
10.3		English Translation of the Amendment to the Service Agreement by and between the Company and Shlomo Pilo, dated December 27, 2025 (incorporated by reference to Exhibit 10.12 in our annual report on Form 10-K filed on March 31, 2026).
10.4		English Translation of the Amendment to the Service Agreement by and between the Company and Ajay Kumar Dhadha, dated December 27, 2025 (incorporated by reference to Exhibit 10.13 in our annual report on Form 10-K filed on March 31, 2026).
31.1*		Certification of Principal Executive Officer Pursuant to Securities Exchange Act Rules 13a-14(a) and 15(d)-14(a).
31.2*		Certification of Principal Financial Officer Pursuant to Securities Exchange Act Rules 13a-14(a) and 15(d)-14(a).
32.1**		Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350.
32.2**		Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350.
101.INS		Inline XBRL Instance Document
101.SCH		Inline XBRL Taxonomy Extension Schema Document
101.CAL		Inline XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF		Inline XBRL Taxonomy Extension Definition Linkbase Document
101.LAB		Inline XBRL Taxonomy Extension Label Linkbase Document
101.PRE		Inline XBRL Taxonomy Extension Presentation Linkbase Document
104*		Cover Page Interactive Data File (formatted in Inline XBRL and contained in Exhibit 101)

* Filed herewith.

11

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

	RAPHAEL PHARMACEUTICAL INC.
Date: May 14, 2026	By:	/s/ Shlomo Pilo
	Name:	Shlomo Pilo
	Title:	Chief Executive Officer (Principal Executive Officer)
Date: May 14, 2026	By:	/s/ Guy Ofir
	Name:	Guy Ofir
	Title:	Chief Financial Officer (Principal Financial Officer)

12

less than 1 thousand. 0001415397 false Q1 --12-31 0001415397 2026-01-01 2026-03-31 0001415397 2026-05-14 0001415397 2026-03-31 0001415397 2025-12-31 0001415397 us-gaap:RelatedPartyMember 2026-03-31 0001415397 us-gaap:RelatedPartyMember 2025-12-31 0001415397 2025-01-01 2025-03-31 0001415397 us-gaap:CommonStockMember 2024-12-31 0001415397 us-gaap:AdditionalPaidInCapitalMember 2024-12-31 0001415397 us-gaap:RetainedEarningsMember 2024-12-31 0001415397 2024-12-31 0001415397 us-gaap:CommonStockMember 2025-01-01 2025-03-31 0001415397 us-gaap:AdditionalPaidInCapitalMember 2025-01-01 2025-03-31 0001415397 us-gaap:RetainedEarningsMember 2025-01-01 2025-03-31 0001415397 us-gaap:CommonStockMember 2025-03-31 0001415397 us-gaap:AdditionalPaidInCapitalMember 2025-03-31 0001415397 us-gaap:RetainedEarningsMember 2025-03-31 0001415397 2025-03-31 0001415397 us-gaap:CommonStockMember 2025-12-31 0001415397 us-gaap:AdditionalPaidInCapitalMember 2025-12-31 0001415397 us-gaap:RetainedEarningsMember 2025-12-31 0001415397 us-gaap:CommonStockMember 2026-01-01 2026-03-31 0001415397 us-gaap:AdditionalPaidInCapitalMember 2026-01-01 2026-03-31 0001415397 us-gaap:RetainedEarningsMember 2026-01-01 2026-03-31 0001415397 us-gaap:CommonStockMember 2026-03-31 0001415397 us-gaap:AdditionalPaidInCapitalMember 2026-03-31 0001415397 us-gaap:RetainedEarningsMember 2026-03-31 0001415397 2020-10-08 0001415397 2020-10-08 2020-10-08 0001415397 us-gaap:CommonStockMember 2021-05-14 2021-05-14 0001415397 2021-05-14 0001415397 2021-05-14 2021-05-14 0001415397 raph:OfficersMember 2026-03-31 0001415397 raph:OfficersMember 2025-12-31 0001415397 raph:InterestShorttermCreditFromARelatedPartyMember 2026-03-31 0001415397 raph:InterestShorttermCreditFromARelatedPartyMember 2025-12-31 0001415397 raph:ConsultingServicesMember 2026-01-01 2026-03-31 0001415397 raph:ConsultingServicesMember 2025-01-01 2025-03-31 0001415397 raph:StockbasedCompensationMember 2026-01-01 2026-03-31 0001415397 raph:StockbasedCompensationMember 2025-01-01 2025-03-31 0001415397 raph:CFOFeeMember 2026-01-01 2026-03-31 0001415397 raph:CFOFeeMember 2025-01-01 2025-03-31 xbrli:shares iso4217:USD iso4217:USD xbrli:shares xbrli:pure

FAQ

How much did Raphael Pharmaceutical (RAPH) lose in Q1 2026?

Raphael Pharmaceutical reported a net loss of $229,000 for the three months ended March 31, 2026. This compares with a $429,000 loss a year earlier, reflecting lower research and development spending and reduced general and administrative costs during the quarter.

What is Raphael Pharmaceutical’s (RAPH) cash position as of March 31, 2026?

As of March 31, 2026, Raphael Pharmaceutical held $1,000 in cash and cash equivalents and total assets of $3,000. This sits against $1,665,000 in current liabilities, leaving the company with a stockholders’ deficit of $1,662,000 on its balance sheet.

Does Raphael Pharmaceutical (RAPH) have a going-concern warning?

Yes. Management states that substantial doubt exists about Raphael Pharmaceutical’s ability to continue as a going concern. With minimal cash, negative equity and no revenue, the company says it must obtain significant additional financing to support operations and planned clinical development activities.

Did Raphael Pharmaceutical (RAPH) generate any revenue in Q1 2026?

No. Raphael Pharmaceutical generated no revenue during the three months ended March 31, 2026, or the comparable 2025 period. The company remains in a development and clinical stage, focused on cannabinoid-based therapies, and has not yet begun commercial product sales.

How have Raphael Pharmaceutical’s (RAPH) expenses changed year over year?

For Q1 2026, research and development expenses were $37,000, down from $72,000, while general and administrative expenses were $186,000, down from $353,000. These declines reduced operating loss to $223,000 from $425,000 in the prior-year quarter.

What funding does Raphael Pharmaceutical (RAPH) expect to need over the next 12 months?

Raphael Pharmaceutical estimates needing about $1 million for research and development and $1 million for capital expenditures over the next 12 months. The company notes existing cash should fund operations only through the third quarter of 2026, so it plans to seek significant additional financing.